In a phase 2 trial of 50 adults with idiopathic normal pressure hydrocephalus awaiting shunt surgery (41 analysed), acetazolamide did not improve a composite gait score vs placebo (difference 0.09 units; p=0.96) and was poorly tolerated: 36% vs 8% stopped for adverse events.
RCTn = 50
Virhammar et al. Safety, tolerability, and efficacy of acetazolamide in idiopathic normal pressure hydrocephalus (DRAIN) in Sweden: a randomised, double-blind, placebo-controlled, phase 2 trial